Mio app training to boost thinking and physical skills in children and teens after cancer
Metacognitive Intervention in Youth With Oncological Disease - the Mio Study
This project will test whether the Mio app's combined thinking exercises and physical tasks can help children and adolescents (ages 8–16) who have finished cancer treatment improve their awareness of thinking and executive skills.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 8 Years to 16 Years |
| Sex | All |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Bern) |
| Trial ID | NCT06464237 on ClinicalTrials.gov |
What this trial studies
The Mio-Study is a randomized controlled trial testing a training app that combines cognitive and physical exercises with metacognitive questions for children and adolescents after cancer. Participants (ages 8–16, German or French speaking) will use the Mio-App and outcomes will include measures of metacognitive thinking and core executive functions, with attention to adherence, age, sex, and fatigue as moderators. The intervention is designed for low-staff delivery and aims to produce durable gains that transfer to school and daily activities. Results will inform whether this interdisciplinary, app-based rehabilitation can support long-term cognitive and motor development in pediatric cancer survivors.
Who should consider this trial
Good fit: Children and adolescents aged 8–16 who had cancer (with or without CNS involvement), are between 3 months before and 10 years after end of treatment, and speak German or French are ideal candidates.
Not a fit: Patients with unstable neurological conditions (e.g., active epilepsy), severe psychiatric disease or learning disability, active substance abuse, inability to follow study procedures, or known non-compliance are unlikely to benefit from this program.
Why it matters
Potential benefit: If successful, the Mio app could strengthen metacognitive awareness, executive functions, and physical skills, helping childhood cancer survivors perform better in school and everyday life.
How similar studies have performed: Combined metacognitive and physical training apps for pediatric cancer survivors are largely novel, with limited prior evidence of long-term, transferable benefits.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed consent as documented by signature (see Informed Consent Form) of participants and / or parents / legal guardians * Age 8-16 years * A diagnosis of cancer either with or without CNS involvement. The participant will be included between 3 months before to 10 years after termination of treatment. * Treatment of cancer including either radiation, chemotherapy and/ or surgical tumor removal * German or French speaking Exclusion Criteria: * Any other instable neurological condition (e.g. epilepsy) * A severe psychiatric disease (e.g., eating disorder) or severe learning disability * Known or suspected non-compliance * Drug or alcohol abuse * Inability to follow the procedures of the study, e.g. due to language problems * Enrolment of the investigator, his/her family members, employees and other dependent persons
Where this trial is running
Bern
- Insespital, University Hospital Bern — Bern, Switzerland (Recruiting)
Study contacts
- Principal investigator: Regula Everts, Prof. Dr. — Division of Neuropaediatrics, Development and Rehabilitation, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland
- Study coordinator: Regula Everts, Prof. Dr. phil.
- Email: regula.everts@insel.ch
- Phone: +41 31 632 84 97
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.